Monica Yang, MD
Basic profileMonica Yang is a Rheumatology/Immunology physician affiliated with University of California, San Francisco. OpenAlex indexes 30 publications with 626 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20241 payment$118
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
56.1%Corticosteroid56.1%Prednisone100%Part D≥15 patientsCancer & immunology
35.5%Folate Analog Metabolic Inhibitor16.8%Rasuvo100%Part D<11 patientsInterleukin-17A Antagonist11%Cosentyx Sensoready (2 Pens)100%Part D<11 patients+ 1 more class in this area
Anti-infectives
8.4%Sulfone8.4%Dapsone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Immune profiling links autoimmune hepatitis to human herpesvirus 6 and relaxin receptor antigens
The Journal of Experimental Medicine
2026 - Nintedanib and Pirfenidone Affect Growth and Differentiation of Human Alveolar Type 2 Cells
bioRxiv (Cold Spring Harbor Laboratory)
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Steven Deeks, MD
University of California, San Francisco
Michael Shlipak, MD
University of California, San Francisco
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”